Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.40 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.40 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.40 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.40 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.40 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.40 |
| ▸ | CFTR | P13569 | 1/20 | 0.39 |
| ▸ | LAP3 | P28838 | 3/20 | 0.38 |
| ▸ | TSHR | P16473 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11814086 | 0.90 | PTPN5 (0.49) | KMT2AMAPTALDH1A1LMNAHPGD | |
| SCHEMBL4912046 | 0.86 | PTPN5 (0.53) | PTPN1 | |
| SCHEMBL11663204 | 0.82 | CYP2C19 (0.42) | KMT2AMAPTCYP2C19HIF1APTPN1 | |
| SCHEMBL11812231 | 0.82 | PTPN5 (0.43) | KMT2AHDAC8HDAC6HSD11B1MEN1 | |
| SCHEMBL6672222 | 0.81 | MAPT (0.46) | KMT2AMAPTCYP2C19HIF1APTPN1 | |
| SCHEMBL3970825 | 0.80 | MAPT (0.47) | KMT2AMAPTSMN1; SMN2HSD11B1MEN1 | |
| SCHEMBL31117250 | 0.80 | CYP1A2 (0.45) | KMT2AMAPTCYP2C19HIF1APTPN1 | |
| SCHEMBL3020859 | 0.78 | PTPN1 (0.52) | PTPN1 | |
| SCHEMBL1195864 | 0.77 | CES1 (0.57) | KMT2AMAPTCYP2C19HIF1APTPN1 | |
| SCHEMBL4447460 | 0.76 | KMT2A (0.57) | KMT2AMAPTCYP2C19HIF1APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7419999-B2 | Gamma lactams as prostaglandin agonists and use thereof | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2008-09-02 | — | — | US | disclosed |
| EP-1556347-A4 | GAMMA LACTAMS AS PROSTAGLANDIN AGONISTS AND USE THEREOF | APPLIED RESEARCH SYSTEMS (AN) | 2006-08-09 | — | — | EP | disclosed |
| US-20050288357-A1 | Gamma lactams as prostaglandin agonists and use thereof | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2005-12-29 | — | — | US | disclosed |
| EP-1556347-A2 | GAMMA LACTAMS AS PROSTAGLANDIN AGONISTS AND USE THEREOF | Applied Research Systems ARS Holding N.V. (AN) | 2005-07-27 | — | — | EP | disclosed |
| WO-2003103604-A2 | GAMMA LACTAMS AS PROSTAGLANDIN AGONISTS AND USE THEREOF | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V (AN) | 2003-12-18 | — | — | WO | disclosed |
| WO-1995028413-A1 | 17β-SUBSTITUTED 3-CARBOXY STEROIDS THAT INHIBIT 5-α-REDUCTASE | SMITHKLINE BEECHAM CORPORATION (US) | 1995-10-26 | — | — | WO | disclosed |
| US-4775692-A | ANTILIPEMIC, ANTICOAGULANT, HYPOTENSIVE, ANTISECRETORY AND ANTIULCER AGENT | TORAY INDUSTRIES, INC. (JP) | 1988-10-04 | — | — | US | disclosed |
| US-4035360-A | TISSUE SPECIFICITY, CRYSTALLINE | PFIZER INC. (US) | 1977-07-12 | — | — | US | disclosed |
| US-4018892-A | Bone deposition by 16-aryl-13,14-dihydro-PGE2 p-biphenyl esters | PFIZER INC. (US) | 1977-04-19 | — | — | US | disclosed |
| US-4000309-A | Bone deposition by 16-aryl-13,14-dihydro-PGE2 p-biphenyl esters | PFIZER INC. (US) | 1976-12-28 | — | — | US | disclosed |
| US-3982016-A | Bone deposition by 16-aryl-13,14-dihydro-PGE2 p-biphenyl esters | PFIZER INC. (US) | 1976-09-21 | — | — | US | disclosed |
| US-3932389-A | ANTIULCER AGENTS | PFIZER INC. (US) | 1976-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288357-A1 | Gamma lactams as prostaglandin agonists and use thereof | PGF, HPGDS, PTGIS | KMT2A 4128/4885MAPT 3715/4885CYP2C19 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.